Blockchain Registration Transaction Record

Gedeptin's Potential in Solid Tumors: New Clinical Data Presented at AACR

GeoVax presents new data on Gedeptin's potential in solid tumors at AACR, showcasing promising results in advanced head and neck cancer patients. The upcoming Phase 2 trial with pembrolizumab signifies a step towards innovative combination therapy for refractory cancers.

This news highlights the progress in gene-directed prodrug therapy for solid tumors, offering hope for patients with advanced and refractory cancers. The promising results from the study and upcoming Phase 2 trial demonstrate the potential of Gedeptin in improving treatment outcomes and leveraging immunotherapy against difficult-to-treat cancers.